Deutsche Bank Ag\ Bio Atla, Inc. Transaction History
Deutsche Bank Ag\
- $240 Billion
- Q3 2024
A detailed history of Deutsche Bank Ag\ transactions in Bio Atla, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 525,353 shares of BCAB stock, worth $688,212. This represents 0.0% of its overall portfolio holdings.
Number of Shares
525,353
Previous 1,195,353
56.05%
Holding current value
$688,212
Previous $1.64 Million
43.56%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding BCAB
# of Institutions
65Shares Held
17.4MCall Options Held
500Put Options Held
33.5K-
Israel Englander Millennium Management LLC | New York, Ny2.66MShares$3.48 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.52MShares$3.3 Million0.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.89MShares$2.47 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.86MShares$2.43 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA874KShares$1.15 Million0.13% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $47.6M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...